Objective To evaluate the efficacy and safety of quetiapine and perphenazine for senile patients with schizophrenia. Methods A total of 196 senile patients with schizophrenia were randomly divided into quetiapine group (n = 98 ) and perphenazine group ( n = 98) for 12-week treatment. They were assessed with Positive and Negative Symptoms Scale ( PANSS) , Treatment Emergent Symptom Scale ( TESS) and laboratory examinations to evaluate the efficacy and side effects. Results There were no significant differences between quetiapine group and perphenazine group in markedly improved rate (68. 4% vs. 66. 3% ) and response rate (89. 8% vs. 87. 8% ). Compared with the baseline, scores of negative symptoms in quetiapine group decreased significantly from the 4th week of the treatment ( P <0.01) . At the end of the treatment, scores of negative symptoms in quetiapine group was significantly lower than that in perphenazine group (P<0.05). Conclusion Quetiapine has fewer side effects and is more effective in treatment of senile schizophrenia, especially for negative symptoms.%目的 评价喹硫平与奋乃静治疗老年精神分裂症的临床疗效和不良反应.方法 对196例老年精神分裂症患者随机分为两组,分别服用喹硫平和奋乃静,疗程12周.采用阳性与阴性症状量表( PANSS)评定疗效,采用治疗中出现的症状量表(TESS)及实验室检查评价不良反应.结果 喹硫平组显效率为68.4％,有效率为89.8％,奋乃静组显效率为66.3％,有效率为87.8％,两组差异无显著性；与治疗前相比喹硫平组阴性症状评分于治疗4周起显著降低(P＜0.01)；治疗12周喹硫平组阴性症状评分低于奋乃静组(P＜0.05).结论 喹硫平对老年精神分裂症疗效较好,尤其是阴性症状,且不良反应少.
展开▼
